Tazarotene
Arazlo, Avage, Duobrii, Fabior, Tazarotene, Tazorac (tazarotene) is a small molecule pharmaceutical. Tazarotene was first approved as Tazorac on 1997-06-13. It is used to treat acne vulgaris and psoriasis in the USA. The pharmaceutical is active against retinoic acid receptor beta, retinoic acid receptor gamma, and retinoic acid receptor alpha. In addition, it is known to target chemerin-like receptor 1 and chemerin-like receptor 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Arazlo, Avage, Fabior, Tazorac (generic drugs available since 2017-04-03)
CombinationsDuobrii
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Halobetasol propionate
+
Tazarotene
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DUOBRII | Bausch Health Companies | N-209354 RX | 2019-04-25 | 1 products, RLD, RS |
Tazarotene
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TAZORAC | Allergan | N-020600 RX | 1997-06-13 | 2 products, RLD, RS |
| AVAGE | Allergan | N-021184 RX | 2002-09-30 | 1 products, RLD, RS |
| TAZORAC | Allergan | N-021184 RX | 2000-09-29 | 2 products, RLD, RS |
| ARAZLO | Bausch Health Companies | N-211882 RX | 2019-12-18 | 1 products, RLD, RS |
| FABIOR | Mayne Group | N-202428 RX | 2012-05-11 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| clindamycin 1% / niacinamide 2% / tazarotene 0.05% | unapproved drug other | 2019-05-09 |
| duobrii | New Drug Application | 2020-01-01 |
| hyaluronic acid sodium salt 0.5% / tazarotene 0.05% | unapproved drug other | 2019-05-09 |
| hyaluronic acid sodium salt 0.5% / tazarotene 0.1% | unapproved drug other | 2019-05-06 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| acne vulgaris | EFO_0003894 | D000152 | L70 |
| psoriasis | EFO_0000676 | D011565 | L40 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Tazarotene, Arazlo, Bausch | |||
| 11311482 | 2038-05-11 | U-2368 | |
| 11679116 | 2036-06-06 | DP | |
| Halobetasol Propionate / Tazarotene, Duobrii, Bausch | |||
| 10251895 | 2036-06-06 | DP | |
| 10426787 | 2036-06-06 | U-2625 | |
| 11648256 | 2036-06-06 | DP | U-2625 |
| 11679115 | 2036-06-06 | DP | U-2625 |
| 8809307 | 2031-11-02 | DP | |
| 10478502 | 2031-11-02 | DP | U-2625 |
| 11839656 | 2031-11-02 | U-2625 | |
| Tazarotene, Fabior, Mayne Pharma | |||
| 8808716 | 2030-02-24 | DP | |
| 10568859 | 2030-02-24 | DP | U-2760 |
| 10688071 | 2030-02-24 | DP | U-2760 |
HCPCS
No data
Clinical
Clinical Trials
67 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acne vulgaris | D000152 | EFO_0003894 | L70 | 8 | 6 | 9 | 7 | — | 30 |
| Psoriasis | D011565 | EFO_0000676 | L40 | 3 | 4 | 6 | 5 | 2 | 19 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | 1 | — | 1 |
| Erythema | D004890 | HP_0010783 | L53.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acne keloid | D000153 | — | L73.0 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | 1 | 2 |
| Paraneoplastic syndromes | D010257 | — | — | — | 1 | — | — | — | 1 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | — | 1 | — | — | — | 1 |
| T-cell lymphoma cutaneous | D016410 | — | C84.A | 1 | 1 | — | — | — | 1 |
| Exanthema | D005076 | HP_0000988 | — | — | 1 | — | — | — | 1 |
| Warts | D014860 | — | B07 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hutchinson's melanotic freckle | D018327 | — | — | — | — | — | — | 1 | 1 |
| Actinic keratosis | D055623 | — | L57.0 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tazarotene |
| INN | tazarotene |
| Description | Tazarotene is the ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin. It has a role as a keratolytic drug, a prodrug and a teratogenic agent. It is a retinoid, a thiochromane, a member of pyridines, an acetylenic compound and an ethyl ester. It is functionally related to a tazarotenic acid. |
| Classification | Small molecule |
| Drug class | arotinoid derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1 |
Identifiers
| PDB | — |
| CAS-ID | 118292-40-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1657 |
| ChEBI ID | 32184 |
| PubChem CID | 5381 |
| DrugBank | DB00799 |
| UNII ID | 81BDR9Y8PS (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CMKLR2
CMKLR2
Organism
Homo sapiens
Gene name
CMKLR2
Gene synonyms
GPR1
NCBI Gene ID
Protein name
chemerin-like receptor 2
Protein synonyms
Chemerin chemokine-like receptor 2, Chemokine-like receptor 2, G protein-coupled receptor 1, G-protein coupled receptor 1, probable G-protein coupled receptor 1
Uniprot ID
Mouse ortholog
Cmklr2 (241070)
chemerin-like receptor 2 (Q8K087)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Tazarotene
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,002 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
613 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use